PO.ET09.10 · 实验与分子治疗
EO1001在EGFR-ECD突变实体瘤模型中的临床前评估：迈向生物标志物导向的治疗
Preclinical evaluation of EO1001 in EGFR-ECD mutant solid tumor models: Toward biomarker-directed therapy
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景：EGFR胞外结构域(ECD)突变——包括EGFRvIII、A289取代、R108变异及相关结构改变——驱动配体非依赖性EGFR激活和高度侵袭性的肿瘤生物学特性。这些突变在胶质母细胞瘤(GBM)中富集，也发生在头颈部、肺部和胃肠道癌症中，在这些癌症中它们与治疗耐药和较差的患者结局相关。EGFR-ECD突变对已获批的EGFR TKI(包括奥希替尼、厄洛替尼、吉非替尼和阿法替尼)具有内在耐药性，因为其结构改变位于ATP结合口袋之外，尽管药物结合仍能保持受体信号传导。EO1001是一种口服生物利用度良好的不可逆泛ErbB抑制剂，旨在靶向野生型和结构改变的ErbB受体。在一项正在进行的1-2a期研究(ANZCTR: ACTRN12620000583943)中，已在EGFR-ECD突变型GBM患者中观察到早期临床获益信号，凸显了机制验证的必要性。为此，我们启动了一项聚焦性临床前项目，评估EO1001在携带临床相关EGFR-ECD变异的患者来源(PDX)细胞培养模型中的活性。
方法：选择PDX GBM细胞培养模型以评估EO1001在代表性EGFR突变状态下的活性。EO1001采用9点剂量反应曲线进行测试，在两个时间点以三复孔运行。细胞活力和增殖使用CellTiter-Glo试验定量。每块板包含一个载体对照、一个DMSO细胞毒性对照，以及一个FDA批准的EGFR TKI作为阳性对照，以将EO1001与一种已知对ECD突变无效的临床用抑制剂进行基准比较。主要终点包括IC50值和最大抑制活性，以确定EO1001是否在EGFR-ECD突变型GBM模型中表现出直接的抗增殖效应。
结果：研究正在进行中，数据将在AACR年会上呈现。计划的分析将界定EO1001是否对EGFR-ECD变异表现出有意义的活性，这些变异代表了一个以对现有EGFR抑制剂耐药和临床结局不佳为特征的、在治疗上难以攻克的亚组。
结论：本临床前项目将进一步探索EO1001在EGFR-ECD突变型癌症中的活性机制，为生物标志物指导的临床开发提供支持。
查看英文原文 English abstract
Background: EGFR extracellular domain (ECD) mutations-including EGFRvIII, A289 substitutions, R108 variants, and related structural alterations-drive ligand-independent EGFR activation and highly aggressive tumor biology. These mutations are enriched in glioblastoma (GBM) and also occur in head and neck, lung, and gastrointestinal cancers, where they are associated with therapeutic resistance and poorer patient outcomes. EGFR-ECD mutations are intrinsically resistant to approved EGFR TKIs, including osimertinib, erlotinib, gefitinib, and afatinib, because the structural alterations lie outside the ATP-binding pocket and preserve receptor signaling despite drug engagement. EO1001 is an orally bioavailable, irreversible pan-ErbB inhibitor designed to target both wild-type and structurally altered ErbB receptors. Early signals of clinical benefit in EGFR-ECD mutant GBM patients have been observed in an ongoing Phase 1-2a study (ANZCTR: ACTRN12620000583943), underscoring the need for mechanistic validation. To address this, we initiated a focused preclinical program assessing EO1001 activity in patient derived (PDX) cell culture models harboring clinically relevant EGFR-ECD variants.
Methods: PDX GBM cell culture models were selected to evaluate EO1001 across representative EGFR mutation states. EO1001 is tested using a 9-point dose-response curve, run in triplicate at two timepoints. Cell viability and proliferation are quantified using CellTiter-Glo assays. Each plate includes a vehicle control, a DMSO cytotoxicity control, and an FDA-approved EGFR TKI as a positive control to benchmark EO1001 against a clinically used inhibitor known to be ineffective in ECD mutations. Primary endpoints include IC50 values and maximal inhibitory activity to determine whether EO1001 demonstrates direct antiproliferative effects in EGFR-ECD mutant GBM models.
Results: Study is ongoing, data will be presented at the AACR annual meeting. Planned analyses will define whether EO1001 demonstrates meaningful activity against EGFR-ECD variants, which represent a therapeutically intractable subgroup characterized by resistance to existing EGFR inhibitors and poor clinical outcomes.
Conclusions: This preclinical program will further explore mechanisms of EO1001's activity in EGFR-ECD mutant cancers, providing support for biomarker-guided clinical development.
利益披露 Disclosure
J. Bacha,
Edison Oncology Holding Corp. Employment, g., Board of Directors, non-salaried role), Independent Contractor, Stock, Stock Option, Travel, Patent.
Rakovina Therapeutics Inc. g., Board of Directors, non-salaried role), Independent Contractor, Stock, Travel, Patent.
Sera Biopharma Inc. g., Board of Directors, non-salaried role), Independent Contractor, Stock, Stock Option.